Health Care • Biotechnology: Pharmaceutical Preparations
$19.42 ▼ -1.45
(-6.95%)
MKT CAP: $151.6M • VOL: 141.0K
52W L $5 52W H $46
CUE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $27.5M | $9.3M | $5.5M |
| YoY Revenue Growth % | +195.7% | +69.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$26.6M | -$41.5M | -$52.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$26.6M | -$40.7M | -$50.7M |
| EBITDA (Normalized) | -$26.4M | -$41.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$21.7M | -$36.3M | -$40.0M |
| Capital Expenditures (CapEx) | $177.0K | $66.0K | — |
| Free Cash Flow (FCF) | -$21.9M | -$36.4M | -$40.0M |
| FCF Margin % | -79.6% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $27.1M | $22.5M | — |
| Total Debt (Short + Long Term) | — | $0 | — |
| Total Stockholders' Equity | $26.4M | $17.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CUE.